The CVD-REAL study presented at the American College of Cardiology 66th Scientific Session asked whether cardiovascular outcomes seen in the EMPA-REG OUTCOME trial could be seen in a real-world environment, and for the entire class of SGLT2 inhibitors, according to AstraZeneca’s Jim McDermott, PhD, vice president for Medical Affairs, Diabetes.
The CVD-REAL study presented at the American College of Cardiology 66th Scientific Session asked whether the cardiovascular effects of SGLT2 inhibitors in a real-world environment (RWE) setting with a broad patient population, according to AstraZeneca’s Jim McDermott, vice president for Medical Affairs, Diabetes. For more on the CVD-REAL trial, see The American Journal of Managed Care®’s coverage of the research findings.
What were the goals and outcomes of the CVD-REAL trial?
CVD-REAL, as you know, is the first large RWE study looking at patients with type 2 diabetes, looking at the all-cause mortality, hospitalization for heart failure, comparing SGLT2s to other glucose-lowering drugs. The purpose of the study was 3 objectives.
The first was, following the results of EMPA-REG, we wanted to see if hospitalization for heart failure was actually a class effect for the agents. Secondly, we wanted to see if the patient population, if these effects were seen in a broader patient population. And then third, we wanted to see if this applied to the real-world setting.
So with these results, we did see that overall the reduction in hospitalization for heart failure, a 39% reduction in hospitalization for heart failure, and a 51% reduction in all-cause mortality, was associated with a class effect. Secondly, we did see that these results were in a broader patient population, and what I’m saying is that 87% of the patients that were in CVD-REAL, which included 300,000 patients, 87% of those patients did not have cardiovascular disease, so these findings obviously are across a broader patient population than what has been studied in the past. Third is that this does demonstrate a real-world evidence effect, that this is what’s going on when patients are being given SGLT2s, treated with SGLT2s by their physicians.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Show Leqvio's Effectiveness in Reducing LDL-C in Patients With ASCVD
April 11th 2024Results from the V-INITIATE trial showed a substantial 60% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 in the inclisiran first group compared with a mere 7% reduction in the usual care group.
Read More
CMS Leaders Describe Their Partnership to Align Programs, Address ACOs’ Concerns
April 11th 2024As CMS’ suite of value-based and accountable care models evolves, leaders from across the agency detailed how they are working together to streamline quality reporting and encourage the move to a population health mindset while addressing providers’ concerns.
Read More